A49T Variant in 5-alpha-reductase Gene and Prostate Cancer Risk in Finland
Author Information
Author(s): Mononen N, Ikonen T, Syrjäkoski K, Matikainen M, Schleutker J, Tammela T L J, Koivisto P A, Kallioniemi O P
Primary Institution: University of Tampere and Tampere University Hospital
Hypothesis
Is the A49T variant in the SRD5A2 gene associated with prostate cancer in the Finnish population?
Conclusion
The A49T variant is not significantly associated with prostate cancer risk in Finnish patients.
Supporting Evidence
- The prevalence of the A49T variant in Finnish prostate cancer patients was 6.0%.
- The prevalence of the A49T variant in benign prostatic hyperplasia patients was 6.3%.
- The prevalence of the A49T variant in population-based controls was 5.8%.
- The odds ratio for prostate cancer associated with the A49T variant was 1.04.
Takeaway
Scientists looked at a gene variant to see if it causes prostate cancer in Finnish men, but they found it doesn't.
Methodology
The study compared the prevalence of the A49T variant in Finnish prostate cancer patients, benign prostatic hyperplasia patients, and population-based controls.
Limitations
The study is limited to the Finnish population and may not apply to other ethnic groups.
Participant Demographics
Finnish prostate cancer patients, benign prostatic hyperplasia patients, and population-based controls.
Statistical Information
P-Value
0.89
Confidence Interval
0.62–1.76
Statistical Significance
p=0.89
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website